Fulgent Genetics, Inc. (FLGT) stock
FLGTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3047% below fair value
$24.21+0.14 (+0.56%)
Close on Nov 17, 2026Market cap $666.15MP/E –Yield –
Fulgent Genetics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Fulgent Genetics's operating cash flow for the twelve months ending Jun 30, 2026 was -$83.70M. For fiscal 2025 it was -$101.64M, down 582.6% from the year before. The highest annual figure on record is $538.58M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$101.64M | -582.6% |
| FY2024 | Dec 31, 2024 | $21.06M | -22.0% |
| FY2023 | Dec 31, 2023 | $27.00M | -89.3% |
| FY2022 | Dec 31, 2022 | $253.52M | -52.9% |
| FY2021 | Dec 31, 2021 | $538.58M | +283.0% |
| FY2020 | Dec 31, 2020 | $140.63M | +2449.0% |
| FY2019 | Dec 31, 2019 | $5.52M | – |
| FY2018 | Dec 31, 2018 | -$675.00K | -150.7% |
| FY2017 | Dec 31, 2017 | $1.33M | -69.8% |
| FY2016 | Dec 31, 2016 | $4.41M | – |
| FY2015 | Dec 31, 2015 | -$969.00K | – |
| FY2014 | Dec 31, 2014 | -$4.40M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$23.76M | – |
| Q1 FY2026 | Mar 31, 2026 | $7.10M | – |
| Q4 FY2025 | Dec 31, 2025 | -$78.14M | -412.3% |
| Q3 FY2025 | Sep 30, 2025 | $11.11M | – |
| Q2 FY2025 | Jun 30, 2025 | -$30.17M | -804.1% |
| Q1 FY2025 | Mar 31, 2025 | -$4.43M | -161.0% |
| Q4 FY2024 | Dec 31, 2024 | $25.02M | +67.5% |
| Q3 FY2024 | Sep 30, 2024 | -$15.51M | -251.5% |
| Q2 FY2024 | Jun 30, 2024 | $4.29M | -56.0% |
| Q1 FY2024 | Mar 31, 2024 | $7.27M | – |
| Q4 FY2023 | Dec 31, 2023 | $14.93M | -55.0% |
| Q3 FY2023 | Sep 30, 2023 | $10.24M | -50.7% |
| Q2 FY2023 | Jun 30, 2023 | $9.74M | -12.5% |
| Q1 FY2023 | Mar 31, 2023 | -$7.91M | -104.2% |
| Q4 FY2022 | Dec 31, 2022 | $33.21M | -56.9% |
| Q3 FY2022 | Sep 30, 2022 | $20.78M | -86.3% |
| Q2 FY2022 | Jun 30, 2022 | $11.13M | -85.4% |
| Q1 FY2022 | Mar 31, 2022 | $188.41M | -19.2% |
| Q4 FY2021 | Dec 31, 2021 | $77.09M | -42.6% |
| Q3 FY2021 | Sep 30, 2021 | $152.20M | +1516.6% |
| Q2 FY2021 | Jun 30, 2021 | $76.11M | – |
| Q1 FY2021 | Mar 31, 2021 | $233.18M | +16970.2% |
| Q4 FY2020 | Dec 31, 2020 | $134.26M | – |
| Q3 FY2020 | Sep 30, 2020 | $9.42M | +141.2% |
| Q2 FY2020 | Jun 30, 2020 | -$4.41M | -753.2% |
| Q1 FY2020 | Mar 31, 2020 | $1.37M | +29.5% |
| Q4 FY2019 | Dec 31, 2019 | -$116.00K | -114.9% |
| Q3 FY2019 | Sep 30, 2019 | $3.90M | – |
| Q2 FY2019 | Jun 30, 2019 | $675.00K | – |
| Q1 FY2019 | Mar 31, 2019 | $1.06M | – |
| Q4 FY2018 | Dec 31, 2018 | $778.00K | – |
| Q3 FY2018 | Sep 30, 2018 | -$105.00K | -121.0% |
| Q2 FY2018 | Jun 30, 2018 | -$57.00K | -110.1% |
| Q1 FY2018 | Mar 31, 2018 | -$1.29M | -185.6% |
| Q4 FY2017 | Dec 31, 2017 | -$1.24M | -199.0% |
| Q3 FY2017 | Sep 30, 2017 | $500.00K | -37.3% |
| Q2 FY2017 | Jun 30, 2017 | $564.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $1.51M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.25M | – |
| Q3 FY2016 | Sep 30, 2016 | $798.00K | – |
See a number that looks wrong?